{"transactions":[{"id":4622269,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49127,"kind":"person","name":"Harris Todd","position":1,"cik":"0001711463","reported_name":"Harris Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-09-17T23:29:28.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":864,"price":9.129,"value":7887.456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":1438495,"source":{"system":"sec-edgar","filing":"0001193125-26-394738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526394738/ownership.xml","form_type":"4"}},{"id":4622268,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49126,"kind":"person","name":"Rueb Yuliya","position":1,"cik":"0002125370","reported_name":"Rueb Yuliya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Finance (PAO)"}}],"security":"Common Stock","published_at":"2026-09-17T23:26:30.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":2925,"price":9.129,"value":26702.325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The previously filed Form 4 overstated the number of securities beneficially owned by the Reporting Person in column 5, due to a clerical error, which has been corrected on this Form 4."}],"balance_after":11258,"source":{"system":"sec-edgar","filing":"0001193125-26-394734","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2125370/000119312526394734/ownership.xml","form_type":"4"}},{"id":4622267,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49128,"kind":"person","name":"Fuhrman Alan","position":1,"cik":"0001303521","reported_name":"Fuhrman Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-17T23:25:03.000Z","date":"2026-09-15","kind":"grant","planned":false,"acquired":true,"shares":951,"price":9.129,"value":8681.679,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units."}],"balance_after":37115,"source":{"system":"sec-edgar","filing":"0001193125-26-394731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526394731/ownership.xml","form_type":"4"}},{"id":4621437,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-09-17T20:31:47.000Z","date":"2026-09-15","kind":"purchase","planned":false,"acquired":true,"shares":9078529,"price":22.029,"value":199990915.341,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by the Fund."}],"balance_after":11616986,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":9078529},"source":{"system":"sec-edgar","filing":"0001231919-26-001194","document":"form4-09172026_080941.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000123191926001194/form4-09172026_080941.xml","form_type":"4"}},{"id":4615929,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":42817,"kind":"person","name":"Verjee Rehan","position":1,"cik":"0001880637","reported_name":"Verjee Rehan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T20:30:11.000Z","date":"2026-09-09","kind":"purchase","planned":false,"acquired":true,"shares":971.8943,"price":20.5784,"value":20000.02966312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $20.5550 to $20.6488. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":971.8943,"source":{"system":"sec-edgar","filing":"0001193125-26-389333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880637/000119312526389333/ownership.xml","form_type":"4"}},{"id":757229,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T21:45:19.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to Jake Simson's continuous service to the Issuer through each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\") and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Mr. Simson's arrangement with the Adviser, Mr. Simson holds the option for the benefit of the Fund, the Nexus Fund, and the Account. Mr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001231919-26-000590","document":"form4-06012026_090607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000123191926000590/form4-06012026_090607.xml","form_type":"4"}},{"id":757228,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":42817,"kind":"person","name":"Verjee Rehan","position":1,"cik":"0001880637","reported_name":"Verjee Rehan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:30:13.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001193125-26-251539","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526251539/ownership.xml","form_type":"4"}},{"id":757227,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41672,"kind":"person","name":"Moran Susan","position":1,"cik":"0001835225","reported_name":"Moran Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:30:11.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001193125-26-251538","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526251538/ownership.xml","form_type":"4"}},{"id":757230,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:30:10.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001193125-26-251537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000119312526251537/ownership.xml","form_type":"4"}},{"id":757226,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":36908,"kind":"person","name":"Gulfo Adele M.","position":1,"cik":"0001647102","reported_name":"Gulfo Adele M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:30:08.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001193125-26-251536","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526251536/ownership.xml","form_type":"4"}},{"id":757225,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:30:05.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001193125-26-251534","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526251534/ownership.xml","form_type":"4"}},{"id":757360,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":42849,"kind":"person","name":"Rothenberg Stephen Michael","position":1,"cik":"0002022747","reported_name":"Rothenberg Stephen Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:30:02.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":13160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":13160,"derivative":{"exercise_price":32.68,"expiration_date":"2036-05-27","underlying":"Common Stock","underlying_shares":13160},"source":{"system":"sec-edgar","filing":"0001193125-26-251532","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022747/000119312526251532/ownership.xml","form_type":"4"}},{"id":788614,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49133,"kind":"person","name":"Warner Douglas J","position":1,"cik":"0001941311","reported_name":"Warner Douglas J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:30:12.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":85000,"derivative":{"exercise_price":33.93,"expiration_date":"2036-05-04","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001193125-26-212116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1941311/000119312526212116/ownership.xml","form_type":"4"}},{"id":788613,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49133,"kind":"person","name":"Warner Douglas J","position":1,"cik":"0001941311","reported_name":"Warner Douglas J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:30:12.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001193125-26-212116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1941311/000119312526212116/ownership.xml","form_type":"4"}},{"id":788580,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49128,"kind":"person","name":"Fuhrman Alan","position":1,"cik":"0001303521","reported_name":"Fuhrman Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:30:11.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":67000,"derivative":{"exercise_price":33.93,"expiration_date":"2036-05-04","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001193125-26-212115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526212115/ownership.xml","form_type":"4"}},{"id":788579,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49128,"kind":"person","name":"Fuhrman Alan","position":1,"cik":"0001303521","reported_name":"Fuhrman Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:30:11.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs."}],"balance_after":36164,"source":{"system":"sec-edgar","filing":"0001193125-26-212115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526212115/ownership.xml","form_type":"4"}},{"id":788578,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49127,"kind":"person","name":"Harris Todd","position":1,"cik":"0001711463","reported_name":"Harris Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:30:09.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":265000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":265000,"derivative":{"exercise_price":33.93,"expiration_date":"2036-05-04","underlying":"Common Stock","underlying_shares":265000},"source":{"system":"sec-edgar","filing":"0001193125-26-212114","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526212114/ownership.xml","form_type":"4"}},{"id":788577,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49127,"kind":"person","name":"Harris Todd","position":1,"cik":"0001711463","reported_name":"Harris Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-07T20:30:09.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":79000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs."}],"balance_after":1437631,"source":{"system":"sec-edgar","filing":"0001193125-26-212114","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526212114/ownership.xml","form_type":"4"}},{"id":788574,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49125,"kind":"person","name":"Ashar Bhavesh","position":1,"cik":"0001849740","reported_name":"Ashar Bhavesh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:30:05.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":50295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option shall vest on May 5, 2027, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":50295,"derivative":{"exercise_price":33.93,"expiration_date":"2036-05-04","underlying":"Common Stock","underlying_shares":50295},"source":{"system":"sec-edgar","filing":"0001193125-26-212112","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526212112/ownership.xml","form_type":"4"}},{"id":788573,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49125,"kind":"person","name":"Ashar Bhavesh","position":1,"cik":"0001849740","reported_name":"Ashar Bhavesh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:30:05.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":15013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs."}],"balance_after":15013,"source":{"system":"sec-edgar","filing":"0001193125-26-212112","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526212112/ownership.xml","form_type":"4"}},{"id":788576,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49126,"kind":"person","name":"Rueb Yuliya","position":1,"cik":"0002125370","reported_name":"Rueb Yuliya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Finance (PAO)"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:30:04.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest monthly following May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":28000,"derivative":{"exercise_price":33.93,"expiration_date":"2036-05-04","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001193125-26-212111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526212111/ownership.xml","form_type":"4"}},{"id":788575,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49126,"kind":"person","name":"Rueb Yuliya","position":1,"cik":"0002125370","reported_name":"Rueb Yuliya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Vice President, Finance (PAO)"}}],"security":"Common Stock","published_at":"2026-05-07T20:30:04.000Z","date":"2026-05-05","kind":"grant","planned":false,"acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on May 5, 2026. 1/4 of the total number of RSUs granted vest on each of the first four anniversaries of May 5, 2026, the vesting commencement date, subject to the Reporting Person's continuous service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes RSUs."}],"balance_after":43354,"source":{"system":"sec-edgar","filing":"0001193125-26-212111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526212111/ownership.xml","form_type":"4"}},{"id":804542,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":36338,"kind":"person","name":"Dable Habib J","position":1,"cik":"0001690773","reported_name":"Dable Habib J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T20:31:02.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":44400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total number of shares of common stock subject to the option vest monthly following April 16, 2026, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":44400,"derivative":{"exercise_price":35.12,"expiration_date":"2036-04-15","underlying":"Common","underlying_shares":44400},"source":{"system":"sec-edgar","filing":"0001193125-26-164090","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526164090/ownership.xml","form_type":"4"}},{"id":826450,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-27T20:44:50.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":53172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.25,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":53172},"source":{"system":"sec-edgar","filing":"0001193125-26-129239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526129239/ownership.xml","form_type":"4"}},{"id":826449,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-27T20:44:50.000Z","date":"2026-03-25","kind":"exercise","planned":false,"acquired":false,"shares":14295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Fully vested."}],"balance_after":53172,"derivative":{"exercise_price":2.25,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":14295},"source":{"system":"sec-edgar","filing":"0001193125-26-129239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526129239/ownership.xml","form_type":"4"}},{"id":826448,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-27T20:44:50.000Z","date":"2026-03-26","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":53172,"price":37.7483,"value":2007152.6076,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.25 to $38.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":28231,"source":{"system":"sec-edgar","filing":"0001193125-26-129239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526129239/ownership.xml","form_type":"4"}},{"id":826447,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-27T20:44:50.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":53172,"price":2.25,"value":119637.0,"ownership":{"direct":true},"balance_after":81403,"source":{"system":"sec-edgar","filing":"0001193125-26-129239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526129239/ownership.xml","form_type":"4"}},{"id":826446,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-27T20:44:50.000Z","date":"2026-03-25","kind":"sale","planned":false,"acquired":false,"shares":14295,"price":36.9714,"value":528506.163,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.95 to $37.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":28231,"source":{"system":"sec-edgar","filing":"0001193125-26-129239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526129239/ownership.xml","form_type":"4"}},{"id":826445,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-27T20:44:50.000Z","date":"2026-03-25","kind":"exercise","planned":false,"acquired":true,"shares":14295,"price":2.25,"value":32163.75,"ownership":{"direct":true},"balance_after":42526,"source":{"system":"sec-edgar","filing":"0001193125-26-129239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526129239/ownership.xml","form_type":"4"}},{"id":838283,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49128,"kind":"person","name":"Fuhrman Alan","position":1,"cik":"0001303521","reported_name":"Fuhrman Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-17T20:59:04.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":1376,"price":9.129,"value":12561.504,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":16164,"source":{"system":"sec-edgar","filing":"0001193125-26-111100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526111100/ownership.xml","form_type":"4"}},{"id":838282,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49127,"kind":"person","name":"Harris Todd","position":1,"cik":"0001711463","reported_name":"Harris Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-17T20:54:28.000Z","date":"2026-03-13","kind":"grant","planned":false,"acquired":true,"shares":1463,"price":9.129,"value":13355.727,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":1358631,"source":{"system":"sec-edgar","filing":"0001193125-26-111083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526111083/ownership.xml","form_type":"4"}},{"id":905373,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:30:07.000Z","date":"2026-02-12","kind":"sale","planned":true,"acquired":false,"shares":5872,"price":33.3666,"value":195928.6752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":146981,"source":{"system":"sec-edgar","filing":"0001193125-26-051534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526051534/ownership.xml","form_type":"4"}},{"id":905372,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2026-02-13T21:30:07.000Z","date":"2026-02-12","kind":"sale","planned":true,"acquired":false,"shares":2128,"price":31.5018,"value":67035.8304,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":152853,"source":{"system":"sec-edgar","filing":"0001193125-26-051534","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526051534/ownership.xml","form_type":"4"}},{"id":935469,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2026-01-20T21:30:13.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":1017,"price":29.0808,"value":29575.1736,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $28.9131 to $29.23. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":154981,"source":{"system":"sec-edgar","filing":"0001193125-26-016651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526016651/ownership.xml","form_type":"4"}},{"id":935468,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2026-01-20T21:30:13.000Z","date":"2026-01-12","kind":"sale","planned":true,"acquired":false,"shares":6983,"price":28.442,"value":198610.486,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $27.9083 to $28.84. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":155998,"source":{"system":"sec-edgar","filing":"0001193125-26-016651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526016651/ownership.xml","form_type":"4"}},{"id":962125,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-20T02:00:04.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":25,"value":250000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. (\"APNG II\") on June 26, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein."}],"balance_after":3823425,"source":{"system":"sec-edgar","filing":"0001193125-25-327254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525327254/ownership.xml","form_type":"4"}},{"id":967744,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Discovery Officer"}}],"security":"Common Stock","published_at":"2025-12-16T21:30:09.000Z","date":"2025-12-12","kind":"sale","planned":true,"acquired":false,"shares":8000,"price":22.6449,"value":181159.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $22.06 to $23.03. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":162981,"source":{"system":"sec-edgar","filing":"0001193125-25-320941","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525320941/ownership.xml","form_type":"4"}},{"id":985202,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49125,"kind":"person","name":"Ashar Bhavesh","position":1,"cik":"0001849740","reported_name":"Ashar Bhavesh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-01T23:17:34.000Z","date":"2025-12-01","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on December 1, 2026, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":300000,"derivative":{"exercise_price":20.81,"expiration_date":"2035-11-30","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-25-304160","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525304160/ownership.xml","form_type":"4"}},{"id":988808,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T22:00:07.000Z","date":"2025-11-21","kind":"sale","planned":true,"acquired":false,"shares":246871,"price":20.2536,"value":5000026.4856,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Alta Partners NextGen Fund II, L.P. (\"APNG II\") on June 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $20.25 to $21.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by APNG II. The Reporting Person is a managing director of the general partner of APNG II and shares voting and investment control with respect to the shares held by APNG II. The Reporting Person disclaims beneficial ownership of all shares held by APNG II, except to the extent of his pecuniary interest therein."}],"balance_after":3833425,"source":{"system":"sec-edgar","filing":"0001193125-25-297551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525297551/ownership.xml","form_type":"4"}},{"id":994015,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-20T00:30:04.000Z","date":"2025-11-19","kind":"sale","planned":true,"acquired":false,"shares":49956,"price":16.3203,"value":815296.9068,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.04 to $16.68. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":170981,"source":{"system":"sec-edgar","filing":"0001193125-25-288529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525288529/ownership.xml","form_type":"4"}},{"id":994014,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-20T00:30:04.000Z","date":"2025-11-18","kind":"sale","planned":true,"acquired":false,"shares":75633,"price":16.0727,"value":1215626.5191,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.24. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":220937,"source":{"system":"sec-edgar","filing":"0001193125-25-288529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525288529/ownership.xml","form_type":"4"}},{"id":997907,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-18T00:03:58.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":17.0713,"value":25606.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.06 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":296570,"source":{"system":"sec-edgar","filing":"0001193125-25-284935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525284935/ownership.xml","form_type":"4"}},{"id":997906,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-18T00:03:58.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":18572,"price":16.1098,"value":299191.2056,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $17.00. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":298070,"source":{"system":"sec-edgar","filing":"0001193125-25-284935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525284935/ownership.xml","form_type":"4"}},{"id":997905,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-18T00:03:58.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":110228,"price":16.0167,"value":1765488.8076,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.13. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":316642,"source":{"system":"sec-edgar","filing":"0001193125-25-284935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525284935/ownership.xml","form_type":"4"}},{"id":997904,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-18T00:03:58.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":1111,"price":16.0036,"value":17779.9996,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.02. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request."}],"balance_after":426870,"source":{"system":"sec-edgar","filing":"0001193125-25-284935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525284935/ownership.xml","form_type":"4"}},{"id":1037993,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49128,"kind":"person","name":"Fuhrman Alan","position":1,"cik":"0001303521","reported_name":"Fuhrman Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-17T21:57:38.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":701,"price":9.129,"value":6399.429,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":14788,"source":{"system":"sec-edgar","filing":"0001193125-25-206439","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312525206439/ownership.xml","form_type":"4"}},{"id":1072375,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49128,"kind":"person","name":"Fuhrman Alan","position":1,"cik":"0001303521","reported_name":"Fuhrman Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-07T20:43:09.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":170000,"derivative":{"exercise_price":10.75,"expiration_date":"2035-08-06","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0000950170-25-105153","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025105153/ownership.xml","form_type":"4"}},{"id":1072373,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":66513,"kind":"person","name":"Bensen Daniel","position":1,"cik":"0001880946","reported_name":"Bensen Daniel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-07T20:40:24.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":170000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":170000,"derivative":{"exercise_price":10.75,"expiration_date":"2035-08-06","underlying":"Common Stock","underlying_shares":170000},"source":{"system":"sec-edgar","filing":"0000950170-25-105140","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025105140/ownership.xml","form_type":"4"}},{"id":1072445,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49133,"kind":"person","name":"Warner Douglas J","position":1,"cik":"0001941311","reported_name":"Warner Douglas J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-07T20:38:02.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on August 7, 2026, and 1/36th of the remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":10.75,"expiration_date":"2035-08-06","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-25-105132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1941311/000095017025105132/ownership.xml","form_type":"4"}},{"id":1072374,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49127,"kind":"person","name":"Harris Todd","position":1,"cik":"0001711463","reported_name":"Harris Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-07T20:36:24.000Z","date":"2025-08-07","kind":"grant","planned":false,"acquired":true,"shares":570000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":570000,"derivative":{"exercise_price":10.75,"expiration_date":"2035-08-06","underlying":"Common Stock","underlying_shares":570000},"source":{"system":"sec-edgar","filing":"0000950170-25-105128","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025105128/ownership.xml","form_type":"4"}},{"id":1105144,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T21:42:47.000Z","date":"2025-06-18","kind":"sale","planned":false,"acquired":false,"shares":9568,"price":9.7822,"value":93596.0896,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.55 to $9.93. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":28231,"source":{"system":"sec-edgar","filing":"0000950170-25-088602","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025088602/ownership.xml","form_type":"4"}},{"id":1105143,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T21:42:47.000Z","date":"2025-06-17","kind":"sale","planned":false,"acquired":false,"shares":10,"price":10.35,"value":103.5,"ownership":{"direct":true},"balance_after":37799,"source":{"system":"sec-edgar","filing":"0000950170-25-088602","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025088602/ownership.xml","form_type":"4"}},{"id":1109931,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T00:06:50.000Z","date":"2025-06-16","kind":"purchase","planned":false,"acquired":true,"shares":11813,"price":10.13,"value":119665.69,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.12 to $10.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":10259291,"source":{"system":"sec-edgar","filing":"0001415889-25-017446","document":"form4-06172025_120645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000141588925017446/form4-06172025_120645.xml","form_type":"4"}},{"id":1109930,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T00:06:50.000Z","date":"2025-06-13","kind":"purchase","planned":false,"acquired":true,"shares":120167,"price":10.2,"value":1225703.4,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.09 to $10.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":10247478,"source":{"system":"sec-edgar","filing":"0001415889-25-017446","document":"form4-06172025_120645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000141588925017446/form4-06172025_120645.xml","form_type":"4"}},{"id":1109929,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-17T00:06:50.000Z","date":"2025-06-12","kind":"purchase","planned":false,"acquired":true,"shares":31307,"price":10.2,"value":319331.4,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.17 to $10.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":10127311,"source":{"system":"sec-edgar","filing":"0001415889-25-017446","document":"form4-06172025_120645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000141588925017446/form4-06172025_120645.xml","form_type":"4"}},{"id":1109928,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T23:05:27.000Z","date":"2025-06-16","kind":"sale","planned":false,"acquired":false,"shares":6814,"price":10.3795,"value":70725.913,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.35 to $10.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":37809,"source":{"system":"sec-edgar","filing":"0000950170-25-086960","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025086960/ownership.xml","form_type":"4"}},{"id":1109927,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T23:05:27.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":10.3055,"value":154582.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":44623,"source":{"system":"sec-edgar","filing":"0000950170-25-086960","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025086960/ownership.xml","form_type":"4"}},{"id":1109926,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-16T23:05:27.000Z","date":"2025-06-12","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":10.3085,"value":309255.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.25 to $10.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":59623,"source":{"system":"sec-edgar","filing":"0000950170-25-086960","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025086960/ownership.xml","form_type":"4"}},{"id":1115173,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-11T23:44:50.000Z","date":"2025-06-09","kind":"purchase","planned":false,"acquired":true,"shares":186850,"price":10.19,"value":1904001.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.14 to $10.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":10096004,"source":{"system":"sec-edgar","filing":"0001415889-25-016759","document":"form4-06112025_110646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000141588925016759/form4-06112025_110646.xml","form_type":"4"}},{"id":1119902,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:43:19.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":213334,"price":10.04,"value":2141873.36,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.48 to $10.18 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":9909154,"source":{"system":"sec-edgar","filing":"0001415889-25-015998","document":"form4-06062025_080635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000141588925015998/form4-06062025_080635.xml","form_type":"4"}},{"id":1119901,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:43:19.000Z","date":"2025-06-04","kind":"purchase","planned":false,"acquired":true,"shares":997864,"price":9.63,"value":9609430.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.32 to $10.15 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":9695820,"source":{"system":"sec-edgar","filing":"0001415889-25-015998","document":"form4-06062025_080635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000141588925015998/form4-06062025_080635.xml","form_type":"4"}},{"id":1127830,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:16:44.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to Jake Simson's continuous service to the Issuer through each vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\") and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Mr. Simson's arrangement with the Adviser, Mr. Simson holds the option for the benefit of the Fund, the Nexus Fund, and the Account. Mr. Simson is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0001415889-25-015139","document":"form4-06022025_080640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000141588925015139/form4-06022025_080640.xml","form_type":"4"}},{"id":1127829,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":42817,"kind":"person","name":"Verjee Rehan","position":1,"cik":"0001880637","reported_name":"Verjee Rehan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:05:12.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0000950170-25-080232","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025080232/ownership.xml","form_type":"4"}},{"id":1127831,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":34495,"kind":"person","name":"Simson Jake","position":1,"cik":"0001863094","reported_name":"Simson Jake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:05:09.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), the RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0000950170-25-080231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863094/000095017025080231/ownership.xml","form_type":"4"}},{"id":1127828,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:05:08.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0000950170-25-080230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025080230/ownership.xml","form_type":"4"}},{"id":1127827,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41672,"kind":"person","name":"Moran Susan","position":1,"cik":"0001835225","reported_name":"Moran Susan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:05:07.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0000950170-25-080228","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025080228/ownership.xml","form_type":"4"}},{"id":1127923,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":42849,"kind":"person","name":"Rothenberg Stephen Michael","position":1,"cik":"0002022747","reported_name":"Rothenberg Stephen Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:05:06.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0000950170-25-080227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022747/000095017025080227/ownership.xml","form_type":"4"}},{"id":1127826,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:05:04.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":22200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2025, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date."}],"balance_after":22200,"derivative":{"exercise_price":9.25,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":22200},"source":{"system":"sec-edgar","filing":"0000950170-25-080226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025080226/ownership.xml","form_type":"4"}},{"id":1200303,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49127,"kind":"person","name":"Harris Todd","position":1,"cik":"0001711463","reported_name":"Harris Todd","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-18T22:44:12.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":1241,"price":9.775,"value":12130.775,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":1357168,"source":{"system":"sec-edgar","filing":"0000950170-25-041551","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025041551/ownership.xml","form_type":"4"}},{"id":1200299,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49128,"kind":"person","name":"Fuhrman Alan","position":1,"cik":"0001303521","reported_name":"Fuhrman Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-18T22:44:00.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":1238,"price":9.775,"value":12101.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan."}],"balance_after":14087,"source":{"system":"sec-edgar","filing":"0000950170-25-041550","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025041550/ownership.xml","form_type":"4"}},{"id":1278866,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:43:00.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":3511,"price":13.7611,"value":48315.2221,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (\"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":443885,"source":{"system":"sec-edgar","filing":"0000950170-25-016385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025016385/ownership.xml","form_type":"4"}},{"id":1278865,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:43:00.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":1890,"price":13.7611,"value":26008.479,"ownership":{"direct":false,"nature":"By Canaan XI L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.75 to $13.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3700705,"source":{"system":"sec-edgar","filing":"0000950170-25-016385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025016385/ownership.xml","form_type":"4"}},{"id":1289687,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":36908,"kind":"person","name":"Gulfo Adele M.","position":1,"cik":"0001647102","reported_name":"Gulfo Adele M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2025-01-31T21:10:03.000Z","date":"2025-01-29","kind":"grant","planned":false,"acquired":true,"shares":37200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total number of shares of common stock subject to the option vest monthly following January 29, 2025, the date of grant, subject to the Reporting Person's continuous service to\nthe Issuer through each vesting date."}],"balance_after":37200,"derivative":{"exercise_price":14.65,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":37200},"source":{"system":"sec-edgar","filing":"0000950170-25-011737","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025011737/ownership.xml","form_type":"4"}},{"id":1294582,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-27T22:09:15.000Z","date":"2025-01-23","kind":"sale","planned":false,"acquired":false,"shares":4825,"price":16.2624,"value":78466.08,"ownership":{"direct":false,"nature":"By Canaan XI L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3702595,"source":{"system":"sec-edgar","filing":"0000950170-25-009278","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025009278/ownership.xml","form_type":"4"}},{"id":1298859,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-21","kind":"sale","planned":false,"acquired":false,"shares":3993,"price":16.3626,"value":65335.8618,"ownership":{"direct":false,"nature":"By Canaan XI L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.58. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer,\nor the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3707420,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1298858,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":461,"price":16.4001,"value":7560.4461,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":447396,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1298857,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-17","kind":"sale","planned":false,"acquired":false,"shares":12808,"price":16.4001,"value":210052.4808,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3711413,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1298856,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":835,"price":16.287,"value":13599.645,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":447857,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1298855,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-21T22:47:17.000Z","date":"2025-01-16","kind":"sale","planned":false,"acquired":false,"shares":6944,"price":16.287,"value":113096.928,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.25 to $16.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3724221,"source":{"system":"sec-edgar","filing":"0000950170-25-007426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025007426/ownership.xml","form_type":"4"}},{"id":1351160,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:47:24.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":566,"price":16.8386,"value":9530.6476,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":448692,"source":{"system":"sec-edgar","filing":"0000950170-24-131084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024131084/ownership.xml","form_type":"4"}},{"id":1351159,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-26T21:47:24.000Z","date":"2024-11-25","kind":"sale","planned":false,"acquired":false,"shares":4706,"price":16.8386,"value":79242.4516,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3731165,"source":{"system":"sec-edgar","filing":"0000950170-24-131084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024131084/ownership.xml","form_type":"4"}},{"id":1366791,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T22:00:07.000Z","date":"2024-11-08","kind":"purchase","planned":false,"acquired":true,"shares":1220681,"price":16.25,"value":19836066.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held directly by the RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), and a separately managed account (the \"Account\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":8697956,"source":{"system":"sec-edgar","filing":"0001415889-24-026718","document":"form4-11132024_051102.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000141588924026718/form4-11132024_051102.xml","form_type":"4"}},{"id":1371568,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:43:56.000Z","date":"2024-11-07","kind":"sale","planned":false,"acquired":false,"shares":2371,"price":17.3181,"value":41061.2151,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":449258,"source":{"system":"sec-edgar","filing":"0000950170-24-124184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024124184/ownership.xml","form_type":"4"}},{"id":1371567,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:43:56.000Z","date":"2024-11-07","kind":"sale","planned":false,"acquired":false,"shares":19720,"price":17.3181,"value":341512.932,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.00 to $17.67. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3735871,"source":{"system":"sec-edgar","filing":"0000950170-24-124184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024124184/ownership.xml","form_type":"4"}},{"id":1371566,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:43:56.000Z","date":"2024-11-06","kind":"sale","planned":false,"acquired":false,"shares":5635,"price":17.1755,"value":96783.9425,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":451629,"source":{"system":"sec-edgar","filing":"0000950170-24-124184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024124184/ownership.xml","form_type":"4"}},{"id":1371565,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-08T21:43:56.000Z","date":"2024-11-06","kind":"sale","planned":false,"acquired":false,"shares":46856,"price":17.1755,"value":804775.228,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $17.75. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3755591,"source":{"system":"sec-edgar","filing":"0000950170-24-124184","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024124184/ownership.xml","form_type":"4"}},{"id":1374351,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-07T00:24:28.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":1126,"price":16.7683,"value":18881.1058,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":457264,"source":{"system":"sec-edgar","filing":"0000950170-24-122639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024122639/ownership.xml","form_type":"4"}},{"id":1374350,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-07T00:24:28.000Z","date":"2024-11-05","kind":"sale","planned":false,"acquired":false,"shares":9367,"price":16.7683,"value":157068.6661,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3802447,"source":{"system":"sec-edgar","filing":"0000950170-24-122639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024122639/ownership.xml","form_type":"4"}},{"id":1374349,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-07T00:24:28.000Z","date":"2024-11-04","kind":"sale","planned":false,"acquired":false,"shares":116,"price":17.006,"value":1972.696,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":458390,"source":{"system":"sec-edgar","filing":"0000950170-24-122639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024122639/ownership.xml","form_type":"4"}},{"id":1374348,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-07T00:24:28.000Z","date":"2024-11-04","kind":"sale","planned":false,"acquired":false,"shares":960,"price":17.006,"value":16325.76,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3811814,"source":{"system":"sec-edgar","filing":"0000950170-24-122639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024122639/ownership.xml","form_type":"4"}},{"id":1378291,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":73,"price":17.1594,"value":1252.6362,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":458506,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378290,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":2878,"price":16.5444,"value":47614.7832,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":458579,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378289,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Commmon Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":604,"price":17.1594,"value":10364.2776,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3812774,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378288,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-11-01","kind":"sale","planned":false,"acquired":false,"shares":23938,"price":16.5444,"value":396039.8472,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3813378,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378287,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-10-31","kind":"sale","planned":false,"acquired":false,"shares":10750,"price":16.4596,"value":176940.7,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":461457,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378286,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-10-31","kind":"sale","planned":false,"acquired":false,"shares":89390,"price":16.4596,"value":1471323.644,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3837316,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378285,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-10-30","kind":"sale","planned":false,"acquired":false,"shares":1189,"price":16.169,"value":19224.941,"ownership":{"direct":false,"nature":"By 2020+ Co-Investment L.P. - Series 7"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\") is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":472207,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378284,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-01T22:18:43.000Z","date":"2024-10-30","kind":"sale","planned":false,"acquired":false,"shares":9889,"price":16.169,"value":159895.241,"ownership":{"direct":false,"nature":"By Canaan XI L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The sole general partner of Canaan XI L.P. (\"Canaan XI\") is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3926706,"source":{"system":"sec-edgar","filing":"0000950170-24-120198","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120198/ownership.xml","form_type":"4"}},{"id":1378292,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":49128,"kind":"person","name":"Fuhrman Alan","position":1,"cik":"0001303521","reported_name":"Fuhrman Alan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-11-01T20:22:45.000Z","date":"2024-10-30","kind":"purchase","planned":false,"acquired":true,"shares":9500,"price":15.9952,"value":151954.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average price for the entire number of shares purchased. The actual prices range between $15.95 to $16.00. Detailed information on the exact number of shares purchased at each price can be obtained from the Issuer upon request."}],"balance_after":12849,"source":{"system":"sec-edgar","filing":"0000950170-24-120099","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024120099/ownership.xml","form_type":"4"}},{"id":1383081,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":86252,"kind":"organization","name":"Boxer Capital Management, LLC","position":1,"cik":"0002018299","reported_name":"Boxer Capital Management, LLC","relationship":{"other":true,"other_text":"See remarks"}}],"security":"Pre-Funded Warrant (right to purchase)","published_at":"2024-10-23T00:49:28.000Z","date":"2024-10-18","kind":"grant","planned":false,"acquired":true,"shares":2000000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On October 18, 2024, Boxer Capital, LLC (\"Boxer\") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the \"Pre-Funded Warrant\").  The Pre-Funded Warrant was issued on October 22, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 18, 2024, Boxer Capital, LLC (\"Boxer\") entered into an exchange agreement with the Issuer, pursuant to which Boxer agreed to exchange 2,000,000 shares of the Issuer's Common Stock for a pre-funded warrant to purchase up to 2,000,000 shares of Common Stock (the \"Pre-Funded Warrant\").  The Pre-Funded Warrant was issued on October 22, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. A holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. A holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are beneficially owned indirectly by Boxer Capital Management, LLC (\"BCM\") as the investment manager of Boxer. BCM disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":2705280,"derivative":{"exercise_price":0.001,"underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0000895345-24-000458","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2018299/000089534524000458/form4.xml","form_type":"4"}}],"next_cursor":"2024-10-23T00:49:28.000000Z,1383081"}